<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="antiviral1\PMC7129535\results\search\drugs\results.xml">
  <result pre="efficacy than standard care. However, the regimen of LPV/RTV plus" exact="ribavirin" post="was shown to be effective against SARS-CoV in vitro."/>
  <result pre="be effective against SARS-CoV in vitro. Another promising alternative is" exact="hydroxychloroquine" post="(200 mg thrice daily) plus azithromycin (500 mg on"/>
  <result pre="Another promising alternative is hydroxychloroquine (200 mg thrice daily) plus" exact="azithromycin" post="(500 mg on day 1, followed by 250 mg"/>
  <result pre="COVID-19 patients and anti-SARS-CoV-2 potency in vitro. The roles of" exact="teicoplanin" post="(which inhibits the viral genome exposure in cytoplasm) and"/>
  <result pre="some viral hemorrhagic fevers. The in vitro antiviral activity of" exact="ribavirin" post="against SARS-CoV was estimated to be at a concentration"/>
  <result pre="are papain-like protease and 3C-like protease.30 The antiviral activity of" exact="lopinavir" post="(LPV; Abbott Laboratories, Lake Bluff, Illinois, US) against MERS-CoV"/>
  <result pre="patients with SARS-CoV-2 infections in 2020 (ChiCTR2000029308). The role of" exact="darunavir" post="(Janssen Pharmaceutica, Beerse, Belgium), also a promising PI against"/>
  <result pre="a rhesus macaque model.35 Additionally, the regimen of LPV/RTV plus" exact="ribavirin" post="was shown to be effective against SARS-CoV in patients"/>
  <result pre="SARS-CoV in patients and in tissue culture.36 Chloroquine, hydroxychloroquine, and" exact="azithromycin" post="Chloroquine is active against malaria as well as autoimmune"/>
  <result pre="cellular receptors of SARS-CoV.38,39 Although the in vitro data of" exact="chloroquine" post="is promising (EC90 of 6.90 μM, using Vero E6"/>
  <result pre="Vero E6 cells infected by SARS-CoV-2), an extensive prescription of" exact="chloroquine" post="in clinical treatment of SARS-CoV-2 is a completely off-label"/>
  <result pre="phase SARS-CoV-2 infected patients.41 Hydroxychloroquine is significantly more potent than" exact="chloroquine" post="in vitro (EC50 values: 0.72 and 5.47 μM, respectively)"/>
  <result pre="potential for drug–drug interactions than chloroquine. Pharmacokinetic models demonstrate that" exact="hydroxychloroquine" post="sulfate is significant superior (5 days in advance) to"/>
  <result pre="hydroxychloroquine sulfate is significant superior (5 days in advance) to" exact="chloroquine" post="phosphate in inhibiting SARS-CoV-2 in vitro.41 The Taiwan CDC"/>
  <result pre="phosphate in inhibiting SARS-CoV-2 in vitro.41 The Taiwan CDC declared" exact="hydroxychloroquine" post="as an important anti-SARS-CoV-2 agent on 26 March, 2020."/>
  <result pre="of glucose-6-phosphatase, QTc prolongation in electrocardiograms, history of allergy to" exact="hydroxychloroquine" post="or who are pregnant or breastfeeding are contraindicated for"/>
  <result pre="or who are pregnant or breastfeeding are contraindicated for receiving" exact="hydroxychloroquine" post="therapy.42 Azithromycin (Pfizer Inc., Manhattan, New York City, NY,"/>
  <result pre="shown to be active in vitro against Ebola viruses.43 Furthermore," exact="azithromycin" post="is thought to have good potential in preventing severe"/>
  <result pre="to patients suffering viral infection.44 According to one recent study," exact="azithromycin" post="(500 mg on day 1, followed by 250 mg"/>
  <result pre="day 2–5) was shown to significantly reinforce the efficacy of" exact="hydroxychloroquine" post="(200 mg three times per day for 10 days)"/>
  <result pre="the treatment of 20 patients with severe COVID-19. Mean serum" exact="hydroxychloroquine" post="concentration was 0.46 ± 0.20 μg/mL. The good clinical"/>
  <result pre="after administration of this combination therapy.42 Consequently, the regimen of" exact="hydroxychloroquine" post="in combination with azithromycin might be a promising alternative"/>
  <result pre="combination therapy.42 Consequently, the regimen of hydroxychloroquine in combination with" exact="azithromycin" post="might be a promising alternative to remdesivir in the"/>
  <result pre="particles in the low micromolar range (IC50, 330 nM).45 Moreover," exact="teicoplanin" post="is able to block the MERS and SARS envelope"/>
  <result pre="SARS envelope pseudotyped viruses as well.45 Mechanistic investigations revealed that" exact="teicoplanin" post="specifically inhibits the activities of host cell's cathepsin L"/>
  <result pre="and subsequent release into the cytoplasm of host cells.46,47 Thus," exact="teicoplanin" post="blocks Ebola virus entry in the late endosomal pathway."/>
  <result pre="late endosomal pathway. These studies indicate the potential role of" exact="teicoplanin" post="and its derivatives (dalbavancin, oritavancin, and telavancin) as novel"/>
  <result pre="(camostat mesylate) Inhibition of endosomal acidification (early endosomal pathway) Chloroquine," exact="hydroxychloroquine" post="(azithromycin is reported to greatly enhance the anti-SARS-CoV-2 activity"/>
  <result pre="dalbavancin, oritavancin, and telavancin) Enhancement of the anti-SARS-CoV-2 activity of" exact="hydroxychloroquine" post="Azithromycin Monoclonal or polyclonal antibodies and other therapies Monoclonal"/>
  <result pre="against COVID-19 has been under evaluation in China recently. Additionally," exact="tocilizumab" post="(Roche Pharmaceuticals, Basel, Switzerland) is a monoclonal antibody that"/>
  <result pre="between 10 and 22 days after admission. Antiviral agents and" exact="methylprednisolone" post="were also administered. Following plasma transfusions, improvements in clinical"/>
  <result pre="receptors.66 For critically ill adults with COVID-19 who develop fever," exact="acetaminophen" post="might be a better choice for temperature control than"/>
  <result pre="by Wu et al. (2020), treatment of COVID-19 patients with" exact="methylprednisolone" post="was shown to decrease the case-fatality risk (HR, 0.38;"/>
  <result pre="(HR, 0.38; 95% CI, 0.20–0.72).68 However, the administered dose of" exact="methylprednisolone" post="is not specified in that investigation. Despite a lack"/>
  <result pre="therapy in adults with COVID-19 and refractory shock (e.g., intravenous" exact="hydrocortisone" post="200 mg per day, as a &quot;shock-reversal�? strategy).68 Moreover,"/>
  <result pre="most promising agent. In addition, favipiravir and combination therapy with" exact="hydroxychloroquine" post="plus azithromycin appear to be acceptable alternatives for treatment"/>
  <result pre="agent. In addition, favipiravir and combination therapy with hydroxychloroquine plus" exact="azithromycin" post="appear to be acceptable alternatives for treatment of COVID-19"/>
  <result pre="ARB need to be prescribed with caution. Compared with NSAIDs," exact="acetaminophen" post="might be a safer agent for treating fever in"/>
  <result pre="USA2020 Feb 1310.1073/pnas.1922083117pii: 201922083 26WangY.FanG.SalamA.HorbyP.HaydenF.G.ChenC.Comparative effectiveness of combined favipiravir and" exact="oseltamivir" post="therapy versus oseltamivir monotherapy in critically ill patients with"/>
  <result pre="201922083 26WangY.FanG.SalamA.HorbyP.HaydenF.G.ChenC.Comparative effectiveness of combined favipiravir and oseltamivir therapy versus" exact="oseltamivir" post="monotherapy in critically ill patients with influenza virus infectionJ"/>
  <result pre="for effective therapyN Engl J Med2020 Mar 1810.1056/NEJMe2005477 34NewsAbidol and" exact="darunavir" post="can effectively inhibit coronavirushttp://www.sd.chinanews.com/2/2020/0205/70145.html[in Chinese] 35FalzaranoD.de WitE.RasmussenA.L.FeldmannF.OkumuraA.ScottD.P.Treatment with interferon-α2b"/>
  <result pre="can effectively inhibit coronavirushttp://www.sd.chinanews.com/2/2020/0205/70145.html[in Chinese] 35FalzaranoD.de WitE.RasmussenA.L.FeldmannF.OkumuraA.ScottD.P.Treatment with interferon-α2b and" exact="ribavirin" post="improves outcome in MERS-CoV-infected rhesus macaquesNat Med1920131313131724013700 36ChuC.M.ChengV.C.HungI.F.WongM.M.ChanK.H.ChanK.S.Role of"/>
  <result pre="treatment of SARS: initial virological and clinical findingsThorax59200425225614985565 37YanY.ZouZ.SunY.LiX.XuK.F.WeiY.Anti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza A H5N1"/>
  <result pre="inhibitor of SARS coronavirus infection and spreadVirol J220056910.1186/1743-422X-2-6916115318 39WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  <result pre="Res30202026927132020029 40CortegianiA.IngogliaG.IppolitoM.GiarratanoA.EinavS.A systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19J Crit Care2020 Mar 1010.1016/j.jcrc.2020.03.005pii:"/>
  <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
  <result pre="coronavirus 2 (SARS-CoV-2)Clin Infect Dis2020 Mar 910.1093/cid/ciaa237pii: S1684-1182 42GautretP.LagierJ.ParolaP.HoangV.T.MeddebL.MailheM.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
  <result pre="virus inhibitors for drug repurposingACS Infect Dis1201531732627622822 44BacharierL.B.GuilbertT.W.MaugerD.T.BoehmerS.BeigelmanA.FitzpatrickA.M.Early administration of" exact="azithromycin" post="and prevention of severe lower respiratory tract illnesses in"/>
  <result pre="scientific evidence that NSAID use worsens COVID-19 symptomsFrom:https://www.drugtopics.com/latest/fda-no-scientific-evidence-nsaid- use-worsens-covid-19-symptoms 66DayM.COVID-19:" exact="ibuprofen" post="should not be used for managing symptoms, say doctors"/>
 </snippets>
</snippetsTree>
